A Phase 2 interventional study of APL-2 in Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2017, is one of 14 in phase 2, and was the 7th registered.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
Browse Anemia, Hemolytic, Autoimmune studies →4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Austria and 15 more countries
Ages 18+
Lakefront Biotherapeutics West LLC · Sites in United States, Australia
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Austria and 15 more countries
Ages 18–100
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Denmark, Germany and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 18 · Phase 3 9
First in 1997; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is close to the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Median enrollment 24 across the 30 interventional studies, 429 across the 1 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Biogen has 1 study filed under Anemia, Hemolytic, Autoimmune — fewer than ten, so there is no comparison to draw.
1 of the studies in Anemia, Hemolytic, Autoimmune with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signs of hemolysis with abnormal values by any of the hemolytic markers:
Able to provide documentary evidence of the following vaccinations within 2 years prior to screening:
Subjects that do not have documentary evidence must be willing to receive any missing vaccinations as outlined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: APL-2
Drug: APL-2
Complement (C3) Inhibitor
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 56 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
Time frame: Part A:From first dose of study drug (Part A Day 1) up to 30days after last dose of study drug in Part A,approximately 366days Part B:From first dose of study drug (Part B Day 1) up to 56days after last dose of study drug in Part B,approximately 980days
Mean Change From Baseline in Hemoglobin at Weeks 48 and 132
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in hemoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Number of Subjects Who Received Red Blood Cell (RBC) Transfusions
The number of on-study RBC transfusions were monitored throughout the treatment period.
Time frame: From Day 1 up to Week 132
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Weeks 48 and 132
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in ARC results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 48 and 132
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in LDH results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Mean Change From Baseline in Haptoglobin at Weeks 48 and 132
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in haptoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Mean Change From Baseline in Indirect Bilirubin at Weeks 48 and 132
Serum chemistry assessments of indirect bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in indirect bilirubin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan
Blood samples were collected for the assessment of Ctrough,max of pegcetacoplan.
Time frame: Pre-dose and 4 hours postdose on Day 1; pre-dose on Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 36, 40, 48, 60, 72, 84, 96, 108, 120 and 132
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 48 and 132
The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. Mean change from baseline in FACIT-Fatigue score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score at Weeks 48 and 132
The LASA consists of 5 single statements asking subjects to rate their perceived level of functioning. Specific domains include physical well-being (fatigue, activity level), emotional well-being (depression, anxiety, stress), spiritual well-being (sense of meaning), and intellectual well-being (ability to think clearly and concentrate). An item for overall quality of life is also included. Each domain scale range from 0 to 10. Where, 0 = as bad as it can be and 10 = as good as it can be. The total score ranging from 0 to 50 and higher scores indicating better quality of life. Mean change from baseline in LASA score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
This Phase 2, prospective pilot study was conducted at 12 sites in Brazil and United States of America in subjects with primary diagnosis of warm antibody autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD) in parallel between 27 March 2018 and 12 September 2022.
| Milestone | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Started | 5 | 6 | 7 | 6 | 0 | 0 |
| Completed | 3 | 3 | 5 | 5 | 0 | 0 |
| Not completed | 2 | 3 | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrew, per investigator | 2 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 5 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 5 | 9 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 3 | 5 |
| Withdrew: Withdrew, per sponsor | 0 | 0 | 0 | 0 | 0 | 1 |
TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 56 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
| Participants | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| All TEAEs | 5 | 5 | 7 | 6 | 5 | 9 |
| Treatment related TEAEs | 4 | 4 | 5 | 4 | 4 | 5 |
| Serious AEs | 3 | 2 | 3 | 2 | 2 | 6 |
| TEAEs leading to study drug discontinuation | 1 | 2 | 1 | 1 | 2 | 2 |
| TEAEs leading to death | 0 | 0 | 1 | 0 | 0 | 1 |
| TEAEs with mild intensity | 2 | 1 | 0 | 0 | 1 | 1 |
| TEAEs with moderate intensity | 0 | 2 | 3 | 3 | 3 | 2 |
| TEAEs with severe intensity | 3 | 2 | 3 | 2 | 1 | 4 |
| TEAEs with life threatening intensity | 0 | 0 | 0 | 1 | 0 | 1 |
Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in hemoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| gram per deciliter (g/dL) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | 0.38 ± 2.347 | 1.93 ± 0.874 | 1.62 ± 1.522 | 2.63 ± 1.694 | — | — |
| Week 132 | — | — | — | — | 0.18 ± 0.626 | -0.20 ± 2.029 |
The number of on-study RBC transfusions were monitored throughout the treatment period.
| Participants | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Number of Subjects Who Received Red Blood Cell (RBC) Transfusions | 2 | 2 | 2 | 1 | 0 | 3 |
Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in ARC results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| 10^9 cells/liter (L) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | -145.050 ± 90.4181 | -130.187 ± 70.4638 | -73.515 ± 73.1983 | -84.064 ± 46.0655 | — | — |
| Week 132 | — | — | — | — | 11.485 ± 4.9787 | 81.585 ± 83.4790 |
Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in LDH results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| international units/L | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | -51.8 ± 39.08 | -169.7 ± 212.89 | -475.8 ± 842.43 | -77.8 ± 73.30 | — | — |
| Week 132 | — | — | — | — | 1.78 ± 46.357 | 35.18 ± 82.727 |
Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in haptoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| g/L | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | 0.715 ± 0.7622 | 0.747 ± 0.7306 | 0.528 ± 0.4961 | 0.172 ± 0.3404 | — | — |
| Week 132 | — | — | — | — | -0.270 ± 0.6364 | -0.335 ± 0.1323 |
Serum chemistry assessments of indirect bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in indirect bilirubin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| micromole/L | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | -10.723 ± 4.2167 | -9.697 ± 5.2220 | -15.879 ± 15.1038 | -17.981 ± 7.0978 | — | — |
| Week 132 | — | — | — | — | 0.195 ± 0.2764 | 4.095 ± 8.7678 |
Blood samples were collected for the assessment of Ctrough,max of pegcetacoplan.
| microgram per milliliter | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan | 629.6 ± 206.66 | 679.7 ± 303.76 | 661.6 ± 192.24 | 807.8 ± 105.12 | 813.6 ± 260.08 | 795.6 ± 204.90 |
The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. Mean change from baseline in FACIT-Fatigue score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| score on a scale | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | -3.8 ± 8.38 | 10.7 ± 5.51 | 0.5 ± 16.33 | 9.0 ± 7.07 | — | — |
| Week 132 | — | — | — | — | -1.0 ± 1.41 | 2.8 ± 7.23 |
The LASA consists of 5 single statements asking subjects to rate their perceived level of functioning. Specific domains include physical well-being (fatigue, activity level), emotional well-being (depression, anxiety, stress), spiritual well-being (sense of meaning), and intellectual well-being (ability to think clearly and concentrate). An item for overall quality of life is also included. Each domain scale range from 0 to 10. Where, 0 = as bad as it can be and 10 = as good as it can be. The total score ranging from 0 to 50 and higher scores indicating better quality of life. Mean change from baseline in LASA score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.
| score on a scale | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Week 48 | 0.0 ± 2.45 | 1.3 ± 4.04 | 0.8 ± 1.72 | 1.0 ± 1.15 | — | — |
| Week 132 | — | — | — | — | 0.0 ± 0.00 | 0.5 ± 1.73 |
Collected over Part A: TEAE data is reported from first dose of study drug (Day 1 of Part A) up to 30 days after the last dose of study drug in Part A, approximately 366 days. Part B: TEAE data is reported from first dose of study drug (Day 1 of Part B) up to 56 days after the last dose of study drug in Part B, approximately 980 days. All-cause mortality: From first dose of study drug (Day 1) up to end of the study, approximately 1346 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1 wAIHA - 270 mg | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Part A: Cohort 1 wAIHA - 360 mg | 0/6 (0%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Part A: Cohort 2 CAD - 270 mg | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Part A: Cohort 2 CAD - 360 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Part B: Cohort 1 wAIHA - 1080 mg | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Part B: Cohort 2 CAD - 1080 mg | 1/9 (11.1%) | 6/9 (66.7%) | 9/9 (100%) |
| Event | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 2/5 | 0/6 | 1/7 | 0/6 | 0/5 | 0/9 |
| Haemoglobin decreasedInvestigations | 0/5 | 0/6 | 0/7 | 0/6 | 1/5 | 1/9 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/5 | 0/6 | 0/7 | 0/6 | 1/5 | 0/9 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 0/6 | 0/7 | 0/6 | 0/5 | 0/9 |
| HaemolysisBlood and lymphatic system disorders | 0/5 | 1/6 | 0/7 | 0/6 | 0/5 | 0/9 |
| Blood calcium increasedInvestigations | 0/5 | 0/6 | 0/7 | 1/6 | 0/5 | 0/9 |
| Blood creatinine increasedInvestigations | 0/5 | 0/6 | 0/7 | 1/6 | 0/5 | 0/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/5 | 0/6 | 0/7 | 1/6 | 0/5 | 0/9 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/5 | 1/6 | 0/7 | 0/6 | 0/5 | 0/9 |
| Cholecystitis acuteHepatobiliary disorders | 0/5 | 0/6 | 1/7 | 0/6 | 0/5 | 0/9 |
| Event | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Part B: Cohort 1 wAIHA - 1080 mg | Part B: Cohort 2 CAD - 1080 mg |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/5 | 0/6 | 3/7 | 1/6 | 3/5 | 0/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/5 | 0/6 | 0/7 | 2/6 | 1/5 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 2/5 | 0/6 | 4/7 | 1/6 | 2/5 | 0/9 |
| ContusionInjury, poisoning and procedural complications | 0/5 | 0/6 | 0/7 | 3/6 | 1/5 | 2/9 |
| DizzinessNervous system disorders | 1/5 | 0/6 | 0/7 | 3/6 | 0/5 | 3/9 |
| HypertensionVascular disorders | 1/5 | 0/6 | 1/7 | 3/6 | 0/5 | 1/9 |
| Weight decreasedInvestigations | 0/5 | 0/6 | 0/7 | 0/6 | 0/5 | 4/9 |
| Vitamin B12 deficiencyMetabolism and nutrition disorders | 1/5 | 1/6 | 3/7 | 1/6 | 0/5 | 0/9 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/5 | 0/6 | 0/7 | 0/6 | 2/5 | 0/9 |
| NauseaGastrointestinal disorders | 2/5 | 0/6 | 2/7 | 2/6 | 2/5 | 1/9 |
The Safety set included all subjects who received at least 1 dose of study drug.
| Age, Continuous(years) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Total |
|---|---|---|---|---|---|
| Mean | 58.6 ± 17.57 | 54.3 ± 22.12 | 68.9 ± 8.51 | 75.7 ± 7.53 | 64.8 ± 16.25 |
| Sex: Female, Male(Participants) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 5 | 15 |
| Male | 2 | 3 | 3 | 1 | 9 |
| Race/Ethnicity, Customized(Participants) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Total |
|---|---|---|---|---|---|
| Black Or African American | 0 | 0 | 0 | 1 | 1 |
| White | 5 | 6 | 7 | 5 | 23 |
| Race/Ethnicity, Customized(Participants) | Part A: Cohort 1 wAIHA - 270 mg | Part A: Cohort 1 wAIHA - 360 mg | Part A: Cohort 2 CAD - 270 mg | Part A: Cohort 2 CAD - 360 mg | Total |
|---|---|---|---|---|---|
| Hispanic Or Latino | 3 | 3 | 1 | 1 | 8 |
| Not Hispanic Or Latino | 2 | 3 | 6 | 5 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Sep 2022, 60 months.
Results were first posted in Dec 2024, 2 years 3 months after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Anemia, Hemolytic, Autoimmune →
Apellis Pharmaceuticals, Inc. →